Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From KineMed Inc.
Recent executive-level company changes and promotions in the biopharma, medical device, and diagnostics industries.
Recent executive-level company changes and promotions in the medical device and diagnostics industries.
Biologics affecting myostatin signaling are at the forefront of the R&D pipeline for sarcopenia, with leading candidates in Phase II from Sanofi/Regeneron, Lilly and Novartis.
FDA’s patient-focused drug development initiative and its Drug Development Tool for qualifying endpoints are galvanizing efforts to establish sarcopenia as an indication for clinical development in what could be a very significant market of elderly patients with weakness and functional disability.
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
- Drug Discovery Tools
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.